Talk:Nilotinib

This is the talk page for discussing improvements to the Nilotinib article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology High‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
High	This article has been rated as High-importance on the project's importance scale.

Medicine C‑class Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
C	This article has been given a rating which conflicts with the project-independent quality rating in the banner shell. Please resolve this conflict if possible.
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Nilotinib.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Page should be updated to indicate the completion of the Phase 1 trial for Parkinsons and to indicate its success. Could also be updated to show that a trial is underway for using the drug for ALS patients with similar initial results to the Parkinsons trial. 162.221.255.140 (talk) 20:43, 2 November 2015 (UTC) Nov 2 2015[reply]

How does cost compare to imatinib ?

- since there was controversy about the high of imatinib and Dasatinib. - Rod57 (talk) 12:10, 18 January 2016 (UTC)[reply]